Family Medicine · Bronx, NY
NPI
1104011618
Since 2007
Specialty
Family Medicine
Code 207Q00000X
Group practices
1
Medicare group memberships
Hospitals
0
Hospital affiliations
1575 Westchester Ave
Bronx, NY, 10472
Phone (718) 842-8900
Groups this clinician bills Medicare through
Medicare paid, 2024
$9,326
266 services
Medicare patients, 2024
50
Average age 74
Drug cost, 2024
$1.8M
17,939 prescriptions
Company payments, 2025
$1,664
From 11 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Ajith K Karayil was code 99213 (office e&m - established), 71 times for 33 patients. In total Ajith K Karayil billed 266 services in 10 codes, and Medicare paid $9,326.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2021-01-20.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99213 Office E&M - Established | Office | 71 | 33 | $63.34 | $4,497 |
| 36415 Venipuncture Blood Collection | Office | 65 | 45 | $8.65 | $562 |
| 93000 Electrocardiogram | Office | 39 | 34 | $7.21 | $281 |
| 99441 Telephone Services | Office | 20 | 15 | $28.22 | $564 |
| 99212 Office E&M - Established | Office | 18 | 13 | $40.26 | $725 |
| 90661 Vaccine Product | Office | 17 | 17 | $36.11 | $614 |
| G0008 Administration of influenza virus vaccine | Office | 17 | 17 | $29.40 | $500 |
By year: 2022 $14K for 356 services; 2023 $11K for 289 services; 2024 $9,326 for 266 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 36415 Venipuncture Blood Collection | 65 | 45 | $8.65 | $562 |
Medicare prescription drug claims, 2024
In 2024, the drug Ajith K Karayil prescribed most often to Medicare patients was Albuterol Sulfate Hfa (Albuterol Sulfate), with 928 prescriptions and refills. In total Ajith K Karayil wrote 17,939 Medicare prescriptions that cost $1.8M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Albuterol Sulfate Hfa Albuterol Sulfate | 928 | 1,044 | 160 | $32K |
| Amlodipine Besylate Generic | 774 | 1,832 | 191 | $4,059 |
| Simvastatin Generic | 773 | 2,054 | 208 | $4,262 |
| Atorvastatin Calcium Generic | 665 | 1,502 | 172 | $5,941 |
| Metformin Hcl Generic | 621 | 1,598 | 158 | $4,660 |
| Omeprazole Generic | 610 | 866 | 110 | $3,881 |
| Metoprolol Succinate Generic | 579 | 1,330 | 136 | $8,010 |
| Diclofenac Sodium Generic | 555 | 629 | 165 | $20K |
| Fluticasone Propionate Generic | 460 | 735 | 136 | $3,641 |
| Famotidine Generic | 444 | 594 | 123 | $2,627 |
| Losartan Potassium Generic | 432 | 1,145 | 116 | $3,980 |
| Losartan-Hydrochlorothiazide Losartan/Hydrochlorothiazide | 427 | 1,098 | 114 | $11K |
| Glipizide Er Glipizide | 375 | 947 | 86 | $5,248 |
| Hydrochlorothiazide Generic | 347 | 785 | 96 | $1,051 |
| Trelegy Ellipta Fluticasone/Umeclidin/Vilanter | 325 | 335 | 53 | $208K |
Brand drugs: 3,400 claims; generic drugs: 13,609 claims; opioid claims: 81.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Ajith K Karayil $1,664 ($1,664 in general payments such as food, travel and fees) from 11 companies. The largest payer was Novo Nordisk Inc with $507.
| Company | Payments | Amount |
|---|---|---|
| Novo Nordisk Inc NVO | 13 | $507 |
| AstraZeneca Pharmaceuticals LP AZN | 13 | $379 |
| Merck Sharp & Dohme LLC MRK | 9 | $169 |
| Otsuka America Pharmaceutical, Inc. 4578.T | 1 | $125 |
| Abbvie Inc. ABBV | 1 | $125 |
| Vanda Pharmaceuticals Inc. VNDA | 1 | $125 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC BHC | 5 | $95.87 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 3 | $64.59 |
| Exact Sciences Corporation EXAS | 1 | $26.96 |
| Bayer Healthcare Pharmaceuticals Inc. BAYN.DE | 1 | $25.57 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.